Home

JONATHAN COUCHMAN

CIK 1265094 · President and CEO · last filed 2025-08-20

JONATHAN COUCHMAN is a President and CEO who has filed 13 SEC Form 4 insider transactions across 2 companies since 2009. 10 SEC filings were submitted jointly with Couchman Family Fund.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

13

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
630 FIFTH AVENUE
SUITE 2260
NEW YORK, NY 10020
Related Filers
Couchman Family Fund — 10 joint filings, latest 2021-08-17
HARPER ASSET MANAGEMENT LLC — 3 joint filings, latest 2020-08-26
Brian James Harper — 3 joint filings, latest 2020-08-26
Michael Cooper Pearce — 3 joint filings, latest 2020-08-26
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ENZO BIOCHEM INC (ENZ) Delisted Director 272,897 $0.31 $85.6K $0 1 2025-01-17
PERNIX THERAPEUTICS HOLDINGS, INC. (GTA) Delisted Director — — — $0 2 2010-01-20

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-08-20 — Disp (D) −605,134 $0
2025-01-17 ENZO BIOCHEM INC (ENZ) Delisted Grant (A) +142,897 $0 EDGAR
2020-03-31 — Buy (P) +2,610,892 $365.1K
2020-03-27 — Buy (P) +1,958,169 $273.8K
2019-01-09 — Buy (P) +2,995,206 $775.8K
2012-04-26 — Other (J) +11,063,578 $0
2010-01-20 PERNIX THERAPEUTICS HOLDINGS, INC. (GTA) Delisted Grant (A) — $0 EDGAR
2009-11-25 PERNIX THERAPEUTICS HOLDINGS, INC. (GTA) Delisted Grant (A) — $0 EDGAR
2008-12-10 — Grant (A) +169,492 $0
2008-07-22 — Grant (A) +12,370 $0
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.